Aclarion, Inc.

Aclarion, Inc. reported a net loss of $(2.75) million for the second quarter of 2026, an increase from $(1.60) million in the same period last year. Revenue for the quarter grew to $25,208. For the six months ended June 30, 2026, the company's net loss was $(5.60) million. The company's cash and cash equivalents increased to $16.29 million, partly due to a registered direct offering that raised approximately $10.4 million in gross proceeds, and management believes current cash will fund operations for at least twelve months.

Aclarion, Inc. announced that its Nociscan platform for chronic low back pain is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking its first site in Indiana. This partnership expands Aclarion's provider network into a new state, aligning the company with a nationally recognized neurosurgery and spine care network. Nociscan leverages biomarkers and AI algorithms to help physicians identify the source of chronic low back pain, offering objective insights that traditional MRI cannot provide.

Aclarion, Inc. announced significant operational and strategic progress in the first half of 2026, highlighted by a 141% year-over-year increase in scan volume and 71% sequential growth. The company expanded reimbursement in the U.K. and launched a U.S. Market Access Program to secure insurance coverage for Nociscan. Aclarion also strengthened its intellectual property with a new AI patent, bringing its total to 65 worldwide, and reported a strong cash position of $16.3 million with no debt, providing a cash runway into the second half of 2027.

Aclarion, Inc. announced the presentation of two abstracts featuring its Nociscan technology at the American Society of Pain & Neuroscience (ASPN) Annual Meeting. The presentations highlighted Nociscan's expanding clinical utility and real-world adoption for chronic low back pain. One abstract detailed an ongoing real-world evidence study with 20 patients, demonstrating successful integration of MRS technology into clinical workflows. The second abstract presented a case study where Nociscan guided basivertebral nerve ablation in a patient without classic Modic changes, resulting in 95% pain relief.

Aclarion, Inc. announced that Texas Spine Care Center has joined its CLARITY (Chronic Low Back Pain Randomized Independent Trial Study) trial as a new clinical site. The CLARITY study aims to demonstrate the clinical and economic value of Aclarion's Nociscan solution in spine surgery, which helps physicians identify the location of chronic low back pain. Texas Spine Care Center's focus on precise pain source identification aligns with Nociscan's capabilities, which has shown a 97% surgical success rate when Nociscan-positive discs are treated. The company anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.

Aclarion, Inc. announced it will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. The company highlighted recent achievements including triple-digit annual growth in Nociscan adoption and a strengthened IP portfolio with a new AI patent, contributing to 64 total patents. Additionally, Aclarion announced a $2.5 million share repurchase program and reported a strong balance sheet with no debt and cash runway into the second half of 2027, alongside an anticipated Q4 2026 interim readout for its CLARITY trial.

Aclarion, Inc. announced a Market Access Program in partnership with PRIA Healthcare to advance its Nociscan® AI-driven platform for chronic low back pain through the U.S. reimbursement process. This initiative aims to expand patient access and support commercial adoption, leveraging PRIA Healthcare's expertise in payer engagement and prior authorization. The company notes Nociscan's prior success in the UK, where it secured payer approval from three of the top four private insurers, as a strong foundation for its U.S. strategy.

Aclarion, Inc. announced that its Board of Directors unanimously rejected an unsolicited public proposal from Echo Lake Capital to acquire the Company at $4.00 per share. The Board determined that the proposal significantly undervalues Aclarion and its strategic potential, and that its structure would disproportionately benefit Echo Lake. Aclarion stated that its cash on the balance sheet would effectively finance Echo Lake's acquisition, allowing them to acquire the Nociscan business and other assets at a substantial discount. The Board remains committed to pursuing credible paths to value creation for all shareholders.

Aclarion, Inc. announced that its stockholders approved all proposals at the 2026 Annual Meeting held on June 4, 2026. Key approvals included the election of seven directors to the Board, the ratification of Haynie & Company as the independent registered public accounting firm, and an amendment to the 2022 equity incentive plan. The company also reported significant business progress, including 196% year-over-year growth in Nociscan scan volumes in Q1 2026 and expanded insurance coverage in the United Kingdom.

Aclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles, expanding the availability of its Nociscan platform in the greater Los Angeles area. This partnership will enable INI to generate real-world evidence comparing Nociscan's chemical biomarker data with bone metabolic information from SPECT-CT, supporting more precise treatment decisions for chronic low back pain. The collaboration aligns with Aclarion's growth strategy and aims to build critical data assets for broader adoption.